These results showed that the IL-6 inhibitors, CIGB-258 and Tocilizumab, were superior in attenuating the acute inflammation of CML than the TNF-α inhibitor (Infliximab), resulting in faster recovery of swimming ability and higher survivability (Figure 7). The gene discussed is IL6; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.